Colgate-Palmolive (CL) officer reports 221-share tax withholding from RSUs in Form 4

Rhea-AI Filing Summary

Colgate-Palmolive Company officer reports small share withholding for taxes. A company officer serving as COO, Eur., APac, Afr Eur, Skin reported a Form 4 transaction involving Colgate-Palmolive common stock. On 12/03/2025, 221 shares of common stock were disposed of at $78.2 per share, coded as transaction type F, which represents shares withheld to cover Medicare and income tax on previously granted restricted stock units under the company’s incentive compensation plan.

After this tax withholding, the officer beneficially owns 10,415 shares directly, 4,538 shares indirectly through the issuer's 401(k) plan trustee, and 60,745 shares indirectly through a trust. The filing notes that the officer continues to hold the original restricted stock units granted, reduced only by the amount required for this tax withholding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tsourapas Panagiotis

(Last) (First) (Middle)

C/O COLGATE-PALMOLIVE COMPANY

300 PARK AVENUE

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
COLGATE PALMOLIVE CO [ CL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	COO, Eur., APac, Afr Eur, Skin

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		F(1)		221	D	$78.2	10,415	D
Common Stock								4,538	I	By Issuer's 401(k) Plan Trustee
Common Stock								60,745	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Payment of Medicare and income tax liability by withholding shares of stock from restricted stock units previously granted under the issuer's incentive compensation plan. The reporting person continues to hold the restricted stock units originally granted, less the amount of this required tax withholding.

	/s/ Kristine Hutchinson, Attorney-in-Fact	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Colgate-Palmolive (CL) report in this Form 4?

The filing reports that a Colgate-Palmolive officer disposed of 221 shares of common stock on 12/03/2025 at a price of $78.2 per share, coded as transaction F.

Why were the 221 Colgate-Palmolive (CL) shares disposed of by the officer?

The 221 shares were withheld to pay Medicare and income tax liabilities arising from restricted stock units previously granted under Colgate-Palmolive’s incentive compensation plan.

How many Colgate-Palmolive (CL) shares does the reporting officer own after the transaction?

Following the transaction, the officer beneficially owns 10,415 Colgate-Palmolive common shares directly, 4,538 shares indirectly via the issuer’s 401(k) plan trustee, and 60,745 shares indirectly through a trust.

What is the role of the reporting person at Colgate-Palmolive (CL)?

The reporting person is an officer of Colgate-Palmolive with the title COO, Eur., APac, Afr Eur, Skin, indicating a senior operating role across several regions and product categories.

Does the officer still hold the original restricted stock units at Colgate-Palmolive (CL)?

Yes. The explanation states that the officer continues to hold the restricted stock units originally granted, reduced only by the portion used for this required tax withholding.

Was this Colgate-Palmolive (CL) insider transaction part of tax-related activity?

Yes. The filing explains that the share disposition represents payment of Medicare and income tax liability by withholding shares from previously granted restricted stock units.